(Q40318857)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

main subject

phase I clinical trial

0 references

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

9

Steven G Reed

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

2

Rhea N Coler

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

4

Valdilea Veloso

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Marilia Santini-Oliveira

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Juçara Parra

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Patricia M Pinto

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Marcia A Ciol

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Robert Bergquist

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Miriam Tendler

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

English

0 references

publication date

10 November 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

586-594

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk

29 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Immunity after treatment of human schistosomiasis mansoni. II. Identification of resistant individuals, and analysis of their immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Schistosoma and related genera: Acquired resistance in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Schistosomiasis vaccine:research to development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Human immune responses to Schistosoma mansoni vaccine candidate antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

In vitro cellular and humoral responses to Schistosoma mansoni vaccine candidate antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Current status of vaccines for schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Vaccination against schistosomiasis and fascioliasis with the new recombinant antigen Sm14: potential basis of a multi-valent anti-helminth vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

An experimental bivalent peptide vaccine against schistosomiasis and fascioliasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Vaccination against Fasciola hepatica infection using a Schistosoma mansoni defined recombinant antigen, Sm14.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

r-Sm14 - pRSETA efficacy in experimental animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Stability improvement of the fatty acid binding protein Sm14 from S. mansoni by Cys replacement: structural and functional characterization of a vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Optimized subunit vaccine protects against experimental leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

The ELISA, enzyme-linked immunosorbent assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Th2 responses in schistosomiasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Host determinants of reinfection with schistosomes in humans: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

The role of cytokines in the formation of the schistosome egg granuloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Elevated proliferation and interleukin-4 release from CD4+ cells after chemotherapy in human Schistosoma haematobium infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Helminth parasites--masters of regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Gender-specific gene expression in Brugia malayi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Dissociation of interleukin-4 and interleukin-5 production following treatment for Schistosoma haematobium infection in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Acquired immune heterogeneity and its sources in human helminth infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Evidence for an association between human resistance to Schistosoma mansoni and high anti-larval IgE levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

Differential recognition patterns of Schistosoma haematobium adult worm antigens by the human antibodies IgA, IgE, IgG1 and IgG4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

The development and use of vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

The importance of adjuvant formulation in the development of a tuberculosis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.027

10.1016/J.VACCINE.2015.10.027

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26571311%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference